3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Lymphoma
24
Lymphoma, Large B-Cell, Diffuse
20
Lymphoma, Non-Hodgkin
16
Lymphoma, Follicular
15
Lymphoma, Mantle-Cell
12
Lymphoma, Large-Cell, Immunoblastic
5
Lymphoma, B-Cell, Marginal Zone
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Lymphoma, Large-Cell, Anaplastic
4
Lymphoma, B-Cell
4
Burkitt Lymphoma
4
Waldenstrom Macroglobulinemia
2
Leukemia
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Oncology Patients Receiving Chemotherapy
1
Multiple Myeloma
1
Lymphoma, AIDS-Related
1
Graft vs Host Disease
1
Interventions
ofatumumab
1
ocrelizumab
1
obinutuzumab
1
ibritumomab tiuxetan
1
Rituximab
1
Paclitaxel
1
Diphenhydramine
1
Cetirizine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Oncology Patients Receiving Chemotherapy
×
ibritumomab tiuxetan
×
Clear all
NCT04189588
2023-10-06
versus
TerSera Therapeutics LLC
Phase 2
Completed
34 enrolled
11 charts